

获得许可的瑞士药品批发





这家拥有药品批发许可证的企业是制药行业的先驱，致力于通过创新的医疗保健解决方案提高生活质量。

公司成立的愿景是满足尚未得到满足的医疗需求，在研发方面堪称楷模，专注于开发治疗罕见和复杂疾病的独特疗法。

在瑞士注册的药品批发商拥有瑞士医药公司颁发的宝贵的

“良好分销规范”（GDP）授权。

该公司拥有全面的药品批发许可证，可以开展国内和国际贸易业务，包括进出口和原材料批发活动。

该公司在温特图尔的总部只有一个小团队，其业务结构是为全球医药市场服务。

战略价值定位

公司的主要资产是其 GDP 许可证，它是进入药品批发行业的重要壁垒。

迄今为止的投资总额为 230,566.18 瑞士法郎，包括完整的运行设置和监管合规。

该企业提供灵活的收购结构，可选择融资全购。

瑞士制药业与税收优惠

瑞士制药业是首屈一指的全球中心，是行业领袖的故乡，并以其卓越的质量和监管而闻名于世。

获得许可的企业可从这一著名的生态系统中获益，在这里，医药产品可获得溢价，并可轻松进入欧盟和全球市场。

瑞士的监管框架虽然严格，但通过与主要市场签订相互承认协议，为国际贸易业务提供了极大的便利。

从税收角度来看，瑞士为制药业务提供了令人信服的优势。

该国的企业税率是欧洲最具竞争力的税率之一，通常在 11.9% 到 21.6% 之间，具体取决于各州。

瑞士的专利盒制度允许对专利相关收入进行优惠征税，对符合条件的收入给予高达 90% 的税收减免。此外，企业还可享受研发超级减免和知识产权的节税处理。

瑞士税收制度的稳定性和透明度，加上广泛的避免双重征税条约网络，为国际医药贸易和投资创造了最佳环境。

GDP

授权的范围涵盖全面的药品批发业务，使收购方能够立即进入受监管的药品分销行业。

虽然目前还没有收入，但已建立的监管框架和运营基础设施为进入瑞士和国际药品批发市场提供了交钥匙解决方案。

TARGET PRICE

\$ 0

GROSS REVENUE

\$ 0

EBITDA

\$ 0

BUSINESS TYPE

制药

COUNTRY

瑞士

BUSINESS ID

L#20250834

要点

注册地址：瑞士温特图尔瑞士温特图尔

实体类型：有限责任公司

银行关系：苏黎世银行

监管许可证：瑞士医药 GDP

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



© 2024 MergersCorp M&A International. All rights reserved.

© 2024 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.



WWW.MERGERSCORP.COM